Acathia Capital Increases Stake in Swedish Savings Platform Futur
3.12.2024 17:46:00 CET | Business Wire | Press release
Acathia Capital has signed its second GP-led secondary transaction thereby increasing its stake in Futur, Sweden's leading pension and savings platform. For this investment Acathia Capital is backed by Montana Capital Partners, a global private equity secondaries investment manager and part of PGIM, the global investment management business of Prudential Financial, Inc. (NYSE: PRU). MCP serves as the main investor in this transaction, alongside a German insurance company.
Since 2019, Acathia Capital and Nordic private equity manager Polaris Private Equity have jointly lead-managed the investment in Futur alongside 3 passive co-investors. In this transaction, Acathia Capital acquired shares from one co-investor through its new vehicle Fjord Pension SCS.
The transaction is another milestone in the journey of Acathia Capital’s successful investment strategy of full conviction investments on a deal-by-deal basis in the financial services sector. Acathia now manages over EUR 300 million AuM.
Futur exemplifies the power of digitalization in the savings market. The company has redefined Sweden’s life insurance market through cost and service leadership, gaining significant market share through end-to-end digitalization and full scalability.
Thanks to its fully digitalized operations, Futur benefits from unique competitive advantages, including:
- Best-in-class partner satisfaction
- Unrivalled cost efficiency
- Leading product innovation capability
Dr. Thomas Schmitt, Managing Partner at Acathia Capital, remarked: “Since our investment in Futur began in 2019, Futur has tripled its assets under management to SEK 240bn. and more than quadrupled its profits, establishing itself as a market leader in Sweden.”
Torgny Johansson, CEO of Futur, says: “We stick to our strategy, to be independent and focus on simplicity for our partners as well as our joint customers.”
About Futur
Futur is a technology-powered pension and savings platform with a life insurance license. It offers long-term savings and insurance cover, with a particular focus on occupational pension and capital insurance. The platform offers leading efficiency, simplicity and access to an independent, quality proofed fund offering. Futur administers over SEK 240bn AuM in 2024 in the form of unit-linked insurance policies.
About Acathia Capital
Acathia Capital specializes in investments in fully regulated insurers and banks across Europe and manages over EUR 300 million in investments for German and Swiss institutional investors. With a track record of creating top-quartile returns for investors, Acathia Capital drives transformative growth in its portfolio companies.
The closing of the transaction is subject to approval of the Swedish Financial Supervisory Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203919861/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom